Since the introduction of angiogenesis as a useful target for cancer therapy, few agents have
been approved for clinical use due to the rapid development of resistance. This problem can …

Age-related macular degeneration (AMD) remains the leading cause of blindness in elderly
people, but the pathophysiology of this disease is still largely unknown. We investigated the …

Aminopeptidase N (APN) is selectively expressed on many tumors and the endothelium of
tumor neovasculature, and may serve as a promising target for cancer diagnosis and …

Anti-angiogenic therapies have generated significant interest for their potential to combat
tumor growth. However, tumor overproduction of pro-angiogenic ligands can overcome …

Most cancer peptide vaccinations tested so far are capable of eliciting a strong immune
response, but demonstrate poor clinical benefits. Since peptide vaccination is safe and well …

Punarnavine, a quinolizidine alkaloid isolated from Boerhaavia diffusa is known to possess
analgesic, anti-inflammatory, hepato-protective, immunomodulatory and anti-proliferative …

Objective: Antiangiogenesis therapy (AAT) has provided substantial benefits regarding
improved outcomes and survival for suitable patients in clinical settings. Therefore, the early …

The identification of numerous deregulated signaling pathways on cancer cells and
supportive stromal cells has revealed several molecular targets whose downregulation can …

For tumor to grow beyond 1–2 mm3 size, tumor recruits new blood vessels referred as
angiogenesis; therefore, targeting angiogenesis can be a promising strategy to suppress …

Intraocular neovascularization is the leading cause of severe visual loss and anti-vascular
endothelial growth factor (VEGF) therapy is currently performed for choroidal …